Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc . (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced... Read More

Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the Human Proteome Organization (HUPO) World Congress 2025, underscoring how deep,... Read More

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc . (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $4.1 million for the third quarter of 2025 Achieved a record quarter for third-party publications and preprints, with more than 60 total to date Ended... Read More

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL Hosting 1x1 meetings on Wednesday, November 12 th Canaccord Genuity MedTech, Diagnostics and Digital Health & Services... Read More

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available... Read More

Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics... Read More

REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. “We are excited to welcome Isaac to our board,” said Omid Farokhzad, Chair and CEO of Seer. “Isaac brings a rare combination of financial leadership and deep sector experience across life science... Read More

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9 th at 12:20 p.m. Eastern Time / 9:20 a.m.... Read More

Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent... Read More

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45 th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13 th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific... Read More

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available... Read More

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic... Read More

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph ® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer’s newest innovation, debuting at the upcoming... Read More

Revenue grew 37%, driven by increased product sales and service revenue REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025 Secured a significant... Read More

REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast... Read More

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Achieved revenue of $4.0 million for the fourth quarter of 2024 and $14.2 million for the full year 2024 Shipped 10 instruments during 2024,... Read More

REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Tuesday, March 4 th at 11:50 a.m. Eastern Time / 8:50 a.m.... Read More

REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025. As a US HUPO Conference sponsor, Seer will host a seminar highlighting novel... Read More

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc . (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live... Read More

REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43 rd Annual Healthcare Conference in San Francisco, CA. Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 15 th at 3:00 p.m.... Read More

REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Seer grew 2,440%... Read More

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA Fireside chat on Monday, November 11 th at 11:30 a.m. Eastern Time Canaccord Genuity MedTech,... Read More

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Achieved revenue of $4.0 million for the third quarter of 2024 Entered into a co-marketing and sales agreement with Thermo Fisher Scientific to further... Read More

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. This strategic... Read More

REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, will showcase the Proteograph Product Suite’s unique ability to deliver deep proteomic insights that complement and strengthen genomic and other “omic” research at the American Society of Human Genetics (ASHG) 2024 Annual Meeting in Denver, Colo., from... Read More

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. , (Nasdaq: SEER), a leading life science innovator shaping the future of proteomics, is set to present significant advancements at the 23rd Human Proteome Organization (HUPO) World Congress in Dresden, Germany, from October 20-24, 2024. As a HUPO sponsor, Seer will showcase novel findings that are driving the adoption and expansion of proteomic science,... Read More

REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the... Read More

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Thursday, September 5 th at 4:05 p.m.... Read More

REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. “Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and... Read More

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44 th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 14 th at 3:00 p.m. Eastern Time /... Read More

REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Achieved revenue of $3.1 million for the second quarter of 2024 Launched the Seer Technology Access Center (STAC) in Europe, providing researchers with... Read More

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast... Read More

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform... Read More

REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific’s Thermo Scientific™ Orbitrap™ Astral™ mass... Read More

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Achieved revenue of $3.1 million for the first quarter of 2024 Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing... Read More

New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass spectrometry REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access... Read More

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast... Read More

REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the... Read More

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44 th Annual Health Care Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat and Q&A session on Monday, March 4 th at 1:30 p.m. Eastern... Read More

Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry and overcomes the limitations of affinity-based methods REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company... Read More

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live... Read More

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42 nd Annual Health Care Conference in San Francisco, CA. Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 10 th at 3:00... Read More

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY. Seer’s management is scheduled to present on Thursday, November 16 th at 1:00 p.m. Eastern Time... Read More

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc . (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 . “After launching our Proteograph XT Assay Kit this year,... Read More

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year period Expanded geographically with two new partners - Danyel... Read More

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that Panome Bio has joined its COE Program. Panome Bio is a metabolomics and proteomics services company that provides biopharma innovators unparalleled access to the biomolecules closest to phenotype using its proprietary Next Generation... Read More

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio... Read More

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY. Fireside chat on Wednesday, September 13 th at 12:15 p.m. Eastern Time Gilmartin Group... Read More

REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year period Launched the Proteograph XT Assay Kit, enabling rapid... Read More

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Thursday, August 10 th at 8:00 a.m. Eastern Time /... Read More

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter of 2023 after market close on Tuesday, August 8, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live... Read More

REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc . (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced an expanded collaboration with Thermo Fisher Scientific, a world leader in serving science, to enable broader access to each company’s respective new technologies. As part of the collaboration, Seer will establish the Seer Technology... Read More

REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced the launch of the Proteograph XT Assay Kit , the latest proteomics assay workflow for the Proteograph Product Suite. This new product increases throughput without compromising performance, making it possible for a single user to process hundreds of... Read More

Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2023. “We started the year off strong with continued... Read More

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of... Read More

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced a new scientific publication in PLOS One demonstrating the unmatched utility of the Proteograph Product Suite to uncover novel insights in human health and disease with deep, unbiased proteomics. Scientists from Seer in collaboration with Luis... Read More

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Seer, Inc . (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022. “I am extremely proud of the Seer team and our accomplishments in our first year of broad commercial availability. The Proteograph Product Suite has been performing... Read More

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat and Q&A session on Wednesday, March 8 th at 9:50 a.m. Eastern Time /... Read More

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2022, after market close, on Thursday, March 2, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.... Read More

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference. Seer’s management is scheduled to present and participate in a Q&A session on Tuesday, January 10 th at 3:00 p.m. Pacific Time / 6:00 p.m.... Read More